Humana
HUM
$403.09
+0.39%
Humana Inc. is a leading US private health insurer specializing in government-sponsored healthcare programs, with nearly all of its medical membership derived from Medicare, Medicaid, and the military's Tricare program, and it also provides complementary services such as primary care, at-home services, and pharmacy benefit management. The company holds a distinct competitive position as a focused player in the Medicare Advantage market, differentiating itself through its integrated care delivery model, including its CenterWell senior-focused clinics. Currently, the investor narrative centers on the company's robust recovery from a challenging 2025, driven by favorable Medicare Advantage rate updates from the Centers for Medicare & Medicaid Services (CMS) that have boosted revenue visibility and sector sentiment, alongside strategic moves like the potential acquisition of MaxHealth to expand its provider network. The stock has experienced a dramatic rerating over the past six months, reflecting renewed confidence in Humana's growth trajectory and margin recovery prospects.…
HUM
Humana
$403.09
Related headlines
Investment Opinion: Should I buy HUM Today?
Rating: Buy. Humana's strong Q1 2026 earnings recovery, accelerating revenue growth, and favorable regulatory environment support a positive outlook. The consensus analyst rating is 'Buy' with an average target of $418.61, implying ~4.3% upside, but we see potential for more given the momentum. Supporting evidence includes: (1) revenue growth of 23.5% YoY in Q1 2026, (2) EPS of $9.85 versus a loss in Q4 2025, (3) gross margin expansion to 14.98% from 11.67%, and (4) free cash flow turning positive at $1.13B. The forward PE of 24.2x is reasonable given the growth trajectory, and the PS ratio of 0.24x is a deep discount to the sector. Key risks include regulatory changes, medical cost inflation, and liquidity constraints. This Buy would be downgraded to Hold if revenue growth decelerates below 10% or if net margins fail to hold above 2%, and upgraded if the stock pulls back to below $350 while fundamentals remain intact. Overall, Humana appears fairly valued relative to its growth prospects, with the recent rally justified by the earnings turnaround.
Sign up to view all
HUM 12-Month Price Forecast
The AI model assesses Humana as bullish over the next 12 months, driven by the strong earnings recovery and supportive regulatory environment. The main risks are regulatory changes and margin sustainability, but the current momentum and valuation support further upside. The stance would be upgraded to high confidence if Q2 2026 earnings confirm the trend, and downgraded to neutral if revenue growth falls below 10% or net margins compress below 1%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Humana's 12-month outlook, with a consensus price target around $418.61 and implied upside of +3.9% versus the current price.
Average Target
$418.61
0 analysts
Implied Upside
+3.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$280 - $513
Analyst target range
Humana is covered by 23 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 2.19 (where 1 is Strong Buy and 5 is Sell). The average target price is $418.61, implying a modest upside of approximately 4.3% from the current price of $401.54. The analyst sentiment is moderately bullish, with a mix of ratings including Overweight, Outperform, and Hold, but no strong sell signals. The target price range spans from a low of $280.00 to a high of $513.00, indicating a wide dispersion of expectations. The high target of $513.00 suggests that some analysts anticipate continued strong performance driven by Medicare Advantage growth and potential operational efficiencies, while the low target of $280.00 reflects concerns about regulatory pressures, competitive dynamics, or margin compression. Recent ratings actions have been mixed, with Wells Fargo upgrading from Equal Weight to Overweight in July 2026, while Morgan Stanley maintains an Underweight stance, highlighting the uncertainty surrounding the stock's future trajectory.
Drowning in data?
Find the real signal!
Bulls vs Bears: HUM Investment Factors
Humana presents a compelling bull case driven by a strong earnings recovery, accelerating revenue growth, and favorable Medicare rate updates, which have fueled a dramatic rerating. However, the bear case highlights the company's thin margins, heavy regulatory dependence, and potential liquidity issues, which could lead to volatility. Currently, the bull evidence is stronger given the concrete Q1 2026 turnaround and supportive policy environment, but the central tension is whether Humana can sustain its margin recovery amid regulatory and competitive pressures. If medical costs remain contained and CMS rates stay favorable, the stock has further upside; if not, the recent gains could quickly reverse.
Bullish
- Revenue growth accelerating strongly: Q1 2026 revenue surged 23.5% YoY to $39.65B, a sharp acceleration from the $29-32B range in prior quarters, driven by strong Medicare Advantage membership growth and favorable rate updates.
- Dramatic profitability turnaround: Net income swung from a -$796M loss in Q4 2025 to a +$1.19B profit in Q1 2026, with EPS of $9.85 versus -$6.61, reflecting improved medical cost trends and pricing discipline.
- Favorable regulatory tailwinds: CMS announced a larger-than-expected Medicare Advantage payment increase for 2027, boosting revenue visibility and sector sentiment, directly benefiting Humana's core business.
- Strong cash flow recovery: Operating cash flow rebounded to $1.25B in Q1 2026 from -$1.85B in Q4 2025, with free cash flow of $1.13B, supporting balance sheet flexibility and potential shareholder returns.
Bearish
- High dependence on government programs: Nearly all medical membership comes from Medicare, Medicaid, and Tricare, making Humana highly sensitive to CMS rate decisions and regulatory changes, which can cause sudden earnings swings.
- Thin net margins remain a concern: Net margin is only 0.92% (Q1 2026), reflecting the high-cost nature of government programs; any adverse medical cost trend could quickly erase profits.
- Liquidity constraints indicated by current ratio: Current ratio of 0.72 suggests potential short-term liquidity pressures, which could limit operational flexibility or force reliance on debt markets.
- Wide analyst target dispersion: Analyst targets range from $280 to $513, indicating significant uncertainty; the low target implies ~30% downside from current levels, reflecting concerns about regulatory and competitive risks.
HUM Technical Analysis
Humana's stock is in a powerful uptrend, with a 1-year price change of +28.7% and a 6-month change of +124.1%, indicating a strong recovery from its 52-week low of $163.11. The current price of $401.54 sits near the upper end of its 52-week range, at approximately 93.6% of the distance from the low to the high of $428.88, suggesting robust momentum and bullish investor sentiment. This positioning near the highs typically reflects strong market conviction, though it also raises the risk of short-term overextension. The stock's beta of 0.745 indicates it is less volatile than the broader market, providing some cushion during pullbacks.
Beta
0.74
0.74x market volatility
Max Drawdown
-47.5%
Largest decline past year
52-Week Range
$163-$429
Price range past year
Annual Return
+29.9%
Cumulative gain past year
| Period | HUM Return | S&P 500 |
|---|---|---|
| 1m | +4.7% | -0.9% |
| 3m | +10.6% | +5.6% |
| 6m | +146.3% | +15.0% |
| 1y | +29.9% | +18.1% |
| ytd | +52.4% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HUM Fundamental Analysis
Humana's revenue trajectory has been robust, with Q1 2026 revenue of $39.65 billion, representing a 23.5% year-over-year growth rate, a significant acceleration from the prior year's quarterly figures which ranged between $29.2 billion and $32.5 billion. This growth is driven by strong performance in its Insurance segment, which generated $38.06 billion in revenue, while the CenterWell segment contributed $6.1 billion, highlighting the core insurance business as the primary growth engine. The company's profitability has improved markedly, with Q1 2026 net income of $1.19 billion and EPS of $9.85, a sharp turnaround from the net loss of $796 million in Q4 2025. Gross margin expanded to 14.98% in Q1 2026 from 11.67% in Q4 2025, and operating margin improved to 3.98% from -3.15%, indicating effective cost management and pricing discipline. Humana's balance sheet remains solid, with a debt-to-equity ratio of 0.73 and a current ratio of 0.72, though the latter suggests potential liquidity constraints. The company generated $1.25 billion in operating cash flow and $1.13 billion in free cash flow in Q1 2026, a strong recovery from the negative free cash flow of -$1.85 billion in Q4 2025, demonstrating improved cash generation capabilities.
Quarterly Revenue
$39.6B
2026-03
Revenue YoY Growth
+23.5%
YoY Comparison
Gross Margin
15.0%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HUM Overvalued?
Given Humana's positive net income, the price-to-earnings (PE) ratio is the most appropriate valuation metric. The trailing PE stands at 25.95x, while the forward PE is 24.24x, indicating that the market expects modest earnings growth in the coming year. The gap between trailing and forward PE is relatively narrow, suggesting that the market's growth expectations are conservative, which could be due to the cyclical nature of the healthcare insurance industry. Compared to the industry average, Humana's valuation appears reasonable, with a PS ratio of 0.24x versus the sector's historical average of around 1.0x, indicating a significant discount. This discount is likely attributable to the company's lower net margin of 0.92% compared to industry peers, reflecting the high-cost nature of government programs. Historically, Humana's PE ratio has ranged from a low of 4.4x in Q1 2026 to a high of 40.1x in Q3 2025, with the current trailing PE of 25.95x sitting near the middle of this range. This suggests that the stock is not excessively overvalued relative to its own history, and the recent earnings recovery supports the current multiple.
PE
26.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 4x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. Humana's net margin of just 0.92% leaves little room for error, and its debt-to-equity ratio of 0.73 indicates moderate leverage. The current ratio of 0.72 suggests potential liquidity constraints, which could be problematic if cash flows weaken. Revenue is heavily concentrated in government programs, making earnings highly sensitive to CMS rate adjustments and utilization trends, as evidenced by the swing from a $796M loss in Q4 2025 to a $1.19B profit in Q1 2026. Market and competitive risks include valuation compression if the stock's recent rally overshoots, as the forward PE of 24.2x is near the higher end of its historical range. Competition from UnitedHealth and CVS, which have also benefited from CMS rate increases, could intensify. Regulatory risk is elevated given the political sensitivity of Medicare Advantage funding, and any adverse policy change could trigger a sector-wide selloff. The stock's beta of 0.745 offers some cushion, but it is not immune to macro-driven risk-off moves. In a worst-case scenario, a combination of unfavorable CMS rate adjustments, rising medical costs, and a broader market correction could drive the stock back toward its 52-week low of $163.11, representing a potential downside of approximately -59% from the current price of $401.54. This would likely require a significant deterioration in fundamentals, such as a return to quarterly losses and negative cash flow, similar to the Q4 2025 period.
FAQ
The key risks for Humana include: (1) Regulatory risk - as a government-dependent insurer, any adverse CMS rate decision could significantly impact earnings, as seen in the past. (2) Financial risk - thin net margins of 0.92% and a current ratio of 0.72 suggest limited buffer against cost shocks. (3) Competitive risk - larger rivals like UnitedHealth and CVS are also vying for Medicare Advantage members, which could pressure growth. (4) Market risk - the stock has a beta of 0.745, so it is less volatile than the market, but a broad selloff could still drag it down. The most severe risk is a combination of regulatory cuts and rising medical costs, which could lead to losses and a sharp decline toward the 52-week low of $163.11.
Based on our analysis, Humana's stock is expected to trade in a range of $280 to $513 over the next 12 months, with a base case target of around $418.61 (the analyst average). The bull case (30% probability) sees the stock reaching $450-$513 if the recovery continues and CMS rates stay favorable. The base case (50% probability) assumes steady growth and margins, with the stock around $400-$450. The bear case (20% probability) could see the stock fall to $280-$350 if there is an earnings miss or regulatory setback. The most likely scenario is the base case, driven by continued execution on the turnaround and stable Medicare Advantage environment.
Humana's valuation appears reasonable relative to its growth and sector. The trailing PE of 25.95x and forward PE of 24.24x are not excessive given the recent earnings recovery, and the PS ratio of 0.24x is a significant discount to the sector average of ~1.0x. Historically, the PE has ranged from 4.4x to 40.1x, so the current level is near the middle. The market is pricing in modest earnings growth, as indicated by the narrow gap between trailing and forward PE. Overall, HUM is fairly valued, with the recent rally justified by the fundamental improvement, but not a bargain.
Humana is a good buy for investors with a medium-to-high risk tolerance who are optimistic about the Medicare Advantage sector. The stock has strong momentum, with a 124% gain over six months, and the Q1 2026 earnings showed a dramatic turnaround to a profit of $1.19B. Analyst consensus is 'Buy' with an average target of $418.61, implying about 4.3% upside, but the wide range ($280-$513) highlights uncertainty. The main downside risk is regulatory changes that could hurt margins, as seen in the past. For those who believe CMS rates will remain favorable and medical costs will stay contained, HUM is a compelling buy; otherwise, it may be prudent to wait for a pullback.
Humana is better suited for a medium-to-long-term investment horizon of 2-3 years, given the cyclical nature of the healthcare insurance industry and the ongoing recovery. The stock has shown high volatility, with a 124% gain in six months, but also a max drawdown of -47.5%, indicating significant swings. Short-term trading could be profitable but risky, as the stock is near its 52-week high and may be overextended. For long-term investors, the key is whether Humana can sustain its margin recovery and grow its Medicare Advantage membership. With a beta of 0.745, it offers some downside protection, but the low dividend yield of 1.39% means returns will depend on capital appreciation. A minimum holding period of 2 years is recommended to ride out potential volatility.
